deltatrials
Completed PHASE4 NCT02730377

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 2
Interventions DPP-4 inhibitors SGLT-2 inhibitors alpha-glucosidase inhibitors liraglutide meglitinides sulphonylurea thiazolidinediones
Updated 30 times since 2017 Last updated: Jun 16, 2020 Started: Mar 28, 2016 Primary completion: Aug 5, 2019 Completion: Aug 12, 2019

Listed as NCT02730377, this PHASE4 trial focuses on Diabetes and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 30 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 25 earlier versions

  1. Oct 2019 — Aug 2020 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  2. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE4

  3. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE4

  4. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE4

  5. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE4

  6. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE4

  7. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE4

  8. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE4

  9. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE4

  10. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE4

  11. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE4

  12. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE4

  13. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE4

  14. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE4

  15. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE4

  16. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE4

  17. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE4

  18. Nov 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE4

  19. Sep 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  20. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE4

  21. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE4

  22. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE4

  23. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE4

  24. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE4

  25. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE4

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novo Nordisk A/S
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adapazarı, Turkey (Türkiye), Albuquerque, United States, Alhambra, United States, Anderson, United States, Arlington, United States, Asheboro, United States, Athens, United States, Aurora, United States, Avon, United States, Bainbridge, United States and 191 more location s